The present application is directed to compounds of Formula I: ##STR00001## compounds comprising these compounds and their uses, for example as medicaments for the treatment of diseases, disorders or conditions mediated or treatable by inhibition of binding between WDR5 protein and its binding partners.

The present invention relates to a novel process for preparing substituted biphenylamides of the general formula (V)

##STR00001##

characterized in that
anilides of the formula (II)

##STR00002##

in a solvent other than tetrahydrofuran,
are reacted with an organoboron compound of the formula (III)

##STR00003##

in the presence of a catalyst system consisting of a ruthenium catalyst, an activator, an oxidizing agent and a metal triflate.

The present invention relates to a novel process for preparing substituted biphenylamides of the general formula (V)

##STR00001##

characterized in that
anilides of the formula (II)

##STR00002##

in a solvent other than tetrahydrofuran,
are reacted with an organoboron compound of the formula (III)

##STR00003##

in the presence of a catalyst system consisting of a ruthenium catalyst, an activator, an oxidizing agent and a metal triflate.

Copper-catalyzed radiofluorination of iodonium salts, iodonium salts, and compounds obtained by copper-catalyzed radiofluorination of iodonium salts are disclosed. Diagnostic and therapeutic methods involving such compounds also are disclosed.

Copper-catalyzed radiofluorination of iodonium salts, iodonium salts, and compounds obtained by copper-catalyzed radiofluorination of iodonium salts are disclosed. Diagnostic and therapeutic methods involving such compounds also are disclosed.

Disclosed herein are novel iodonium analogs having anticancer and anti-inflammatory activity.

Disclosed herein are novel iodonium analogs having anticancer and anti-inflammatory activity.